Key result
Recurrent episodes of multiple sclerosis were significantly associated with lower levels of human myxovirus resistance protein A (p=0.001) and higher levels of interleukins 10, 12, and 17 (p=0.008).
Why the study?
The pathogenesis of multiple sclerosis remains incompletely understood, prompting research into immune-system biomarkers linked to disease mechanisms.
Are biomarker levels of previous viral infections associated with recurrent episodes in multiple sclerosis patients?
Case-Control (n=68)
Are biomarker levels of previous viral infections associated with recurrent episodes in multiple sclerosis patients?
p-value: p=0.001
Biomarkers of previous viral infections, specifically interleukins and MxA, show differential levels in MS patients with recurrent episodes compared to those without.
Supports immune biomarker exploration in MS; leaves open clinical utility pending larger validation studies.
"Although multiple sclerosis (MS) is the most common neurological disease of young adults, afflicting hundreds of thousands of people worldwide, its pathogenesis is still only incompletely understood. There seems to be substantial heterogeneity in disease mechanisms, but in the majority of cases an autoimmune origin or at least a decisive autoimmune component is postulated. Therefore, pathogenic research focuses on different players programmed by the immune system. In this study, biomarkers such as Human myxovirus resistance protein A (MxA), Anti-EBNA antibody and Interleukin S10-12- 17 have been tested. Study of hypotheses show that: Interleukin levels in the blood of MS patients in the experimental group (patients with recurrence) is higher than controls (patients without recurrence condition). The level of anti-EBNA antibody in MS patients in other groups (patients with recurrent) and control group (patients without recurrence condition) is high. The level of the human myxovirus resistance protein A (MxA) in patients with multiple sclerosis in the experimental group (patients with recurrence) is less than the control group (patients without recurrence condition). The level of anti-EBNA antibody in MS patients in other groups (patients with recurrent) and control group (patients without recurrence condition) is high."
No takes yet. Share an insight, caveat, or question.
Mohammad Sadegh Hashemzadeh (2022) conducted a case-control in Multiple Sclerosis (n=68). Previous viral infection biomarkers (MxA, Anti-EBNA, Interleukins 10, 12, 17) vs. Multiple sclerosis patients without recurrence was evaluated on Levels of human myxovirus resistance protein A (MxA) and Interleukins 10, 12, and 17 (p=0.001). Recurrent episodes of multiple sclerosis were significantly associated with lower levels of human myxovirus resistance protein A (p=0.001) and higher levels of interleukins 10, 12, and 17 (p=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: